The lower risk MDS patient at risk of rapid progression. [electronic resource]
Producer: 20101221Description: 1551-5 p. digitalISSN:- 1873-5835
- Age Factors
- Antigens, Differentiation -- blood
- Antineoplastic Agents -- therapeutic use
- Caspase 3 -- biosynthesis
- Chromosome Aberrations
- Cyclin-Dependent Kinase Inhibitor p15 -- biosynthesis
- Cytokines -- therapeutic use
- DNA Methylation -- genetics
- Erythrocyte Transfusion
- Female
- Ferritins -- blood
- Fibrosis
- Gene Expression Regulation -- genetics
- Humans
- Immunosuppression Therapy
- Immunosuppressive Agents -- therapeutic use
- Inhibitor of Apoptosis Proteins
- Lenalidomide
- Leukocyte Count
- Lipoproteins, LDL -- blood
- Lymphoid Enhancer-Binding Factor 1 -- biosynthesis
- Male
- Microtubule-Associated Proteins -- biosynthesis
- Mutation
- Myelodysplastic Syndromes -- diagnosis
- Platelet Count
- Prognosis
- Proto-Oncogene Proteins -- biosynthesis
- Proto-Oncogene Proteins c-bcl-2 -- biosynthesis
- Receptor Protein-Tyrosine Kinases -- biosynthesis
- Risk Factors
- Sex Factors
- Survivin
- Thalidomide -- analogs & derivatives
- alpha Catenin -- biosynthesis
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.